Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02407119 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Jun 2022 to Jun 2030v9
  2. 3 versions Re-verified since Mar 13, 2019, no change to tracked fieldsv6-v8
  3. Primary endpoints revised (2)v5
  4. Study completion date: Jun 2022
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study description expanded, about 5 words
    v4
  5. Enrollment target: estimated 400 to confirmed 470
    • Primary completion date changed from estimate of Mar 2016 to Jun 2016
    v3
  6. Primary endpoints: 1 to 2
    • Secondary endpoints expanded, about 7 words
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study evaluates whether Helicobacter pylori eradication improves precancerous lesions including glandular atrophy and intestinal metaplasia as well as metachronous cancers or dysplasias after endoscopic mucosal resection for gastric cancer.
Trial Details
NCT Number NCT02407119
Lead Sponsor National Cancer Center, Korea
Conditions
(from sponsor)		 Helicobacter Pylori Infection, Early Gastric Cancer, Endoscopic Resection
Related terms Atrophy, Stomach Neoplasms
Enrollment 470 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov